Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity
Abstract
The effect of chronic treatment with vitamin E (VE) on acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity, as assessed by striatal dopamine (DA) depletion, was studied. Male C57B1/6J mice were fed VE (48 mg kg-1 per day, intragastric) for 4, 8, or 12 weeks prior to administration of MPTP (20 mg kg-1, i.p. x 3, 2 h intervals) or its diluent. Brain VE concentration was increased by exogenous supplements for 12 weeks. Striatal DA content was reduced by 85% to 90% after MPTP in control and VE-treated mice. Mice with elevated cerebral VE were not protected from MPTP toxicity, with DA content as an indicator. In conclusion, these findings indicate that moderate elevation of brain VE is not adequate for protecting DA-containing neurons against the toxic actions of a high dose of MPTP.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Systematic administration of vitamin E did not show protective effect in laboratory animals including inability to attenuate dopamine depletion.
“Systematic administration of vitamin E did not show a protective effect in laboratory animals including the inability to attenuate dopamine depletion (Martinovits et al. 1986; Gong et al. 1991).”
From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Gong et al. 1991
Cited by
Sorted by citations
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638 · see citing works
Oxidative stress: Free radical production in neural degeneration
Götz, M. E., Künig, G., Riederer, P. F., & Youdim, M. B. H. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90055-8 · Cited by 479 · see citing works
Antioxidants in Central Nervous System Diseases: Preclinical Promise and Translational Challenges
Kamat, C. D., Gadal, S., Mhatre, M., Williamson, K. S., Pye, Q. N., & Hensley, K. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15314 · Cited by 237 · see citing works
“Independent, but roughly contemporaneous, studies reported that α - tocopherol, ascorbate, dimethyl sulfoxide, cysteamine or sodium selenite offered no protection against MPTP in the mouse model [55,97].”
The emerging role of nutrition in Parkinson's disease
Seidl, S. E., Santiago, J. A., Bilyk, H. T., & Potashkin, J. A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00036 · Cited by 209 · see citing works
“Oral pretreatment with EGCG prevented dopaminergic neuron loss in MPTP-treated mice (Levites et al., 2001).”
BackgroundThe Promise of Neuroprotective Agents in Parkinson?s Disease
Seidl, S. E., & Potashkin, J. A. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00068 · Cited by 141 · see citing works
“…DA loss H (Fernandez-Calle et al., 1992; LeWitt, 1994; Morens et al., 1996) Clinical trials also show no neuroprotective benefit of taking vitamin E A (Gong et al., 1991; Chi et al., 1992) Striatal DA was not attenuated by pretreatment of vitamin E C (Offen et al., 1996) Vitamin E has no…”
BackgroundVitamin E and neurodegenerative diseases
Ricciarelli, R., Argellati, F., Pronzato, M. A., & Domenicotti, C. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.01.004 · Cited by 128 · see citing works
Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View
Filograna, R., Beltramini, M., Bubacco, L., & Bisaglia, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030102718 · Cited by 110 · see citing works
“The results achieved by supplementing vitamin E to animal models of PD were often contradictory [42-45].”
BackgroundMiyake, Y., Fukushima, W., Tanaka, K., Sasaki, S., Kiyohara, C., Tsuboi, Y., Yamada, T., Oeda, T., Miki, T., Kawamura, N., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03088.x · Cited by 111 · see citing works
“MPTP-induced neurodegeneration was not worsened by genetic vitamin E deficiency, whereas oral administration of vitamin E resulted in the partial protection of striatal dopaminergic terminals against MPTP toxicity in a mouse model using a-tocopherol transfer protein knockout mice [33].”
BackgroundInfluentialVitamin E therapy in Parkinson's disease
Fariss, M. W. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00158-6 · Cited by 100 · see citing works
“Likewise, subsequent studies have reported that MPTP-induced depletion of striatal dopamine could not be attenuated by pre-treatment of mice with a daily oral gavage of a-tocopherol (48 mg/kg body wt.) for 4, 8 or 12 weeks (Gong et al., 1991; Chi et al., 1992).”
Bogaerts, V., Theuns, J., & Broeckhoven, C. V. (2007) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00342.x · Cited by 86 · see citing works
“However in vivo studies did not consistently find positive effects of vitamin E administration (Gong et al. 1991; Roghani & Behzadi 2001).”
BackgroundNeuroprotective effects of riluzole on a model of Parkinson's disease in the rat
Barnéoud, P., Mazadier, M., Miquet, J.-M., Parmentier, S., Dubédat, P., Doble, A., & Boireau, A. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00249-7 · Cited by 81 · see citing works
Antioxidant Therapeutics in Parkinson’s Disease: Current Challenges and Opportunities
Duarte-Jurado, A. P., Gopar‐Cuevas, Y., Cárdenas, O. S., Loera‐Arias, M. D. J., Montes‐de‐Oca‐Luna, R., García‐García, A., & Rodríguez‐Rocha, H. (2021) · Antioxidants · doi:10.3390/antiox10030453 · Cited by 82 · see citing works
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77 · see citing works
Pardo, B., Mena, M. A., Fahn, S., & de Yébenes, J. G. (1993) · Movement Disorders · doi:10.1002/mds.870080305 · Cited by 65 · see citing works
Antioxidant strategies in protection against neurodegenerative disorders
Tan, D.-X., Manchester, L. C., Sainz, R. M., Mayo, J. C., Alvares, F. L., & Reiter, R. J. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.10.1513 · Cited by 57 · see citing works
Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection
Kincses, Z. T., & Vécsei, L. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00150.x · Cited by 37 · see citing works
“On the other hand, vitamin E pretreatment does not attenuate MPTP striatal neurotoxicity [270,271] and a genetic vitamin E deficiency does not affect MPTP susceptibility [272].”
BackgroundVatassery, G. T. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb17092.x · Cited by 35 · see citing works
Fonck, C., & Baudry, M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02675-1 · Cited by 31 · see citing works
Sanchez‐Ramos, J., Song, S., Facca, A., Basit, A., & Epstein, C. J. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010058.x · Cited by 19 · see citing works
“…andposttreatmentwith various dosesof the antioxidantsascorbicacid, a-tocopherol,/3-carotene,sodium selenite,dimethyl sulfoxide, and cysteamineall failed to attenuateMPTPinducedstriatal DA depletionin rodents (Martinovits et al., 1986; Gong et al., 1991) and in marmosets (Mihatschet al., 1991).”
BackgroundCouto, D., Santinha, D. R., Melo, T., Ferreira‐Fernandes, E., Videira, R. A., Campos, A. M. F., Fardilha, M., Domingues, P. M., & Domingues, M. R. (2015) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2015.08.014 · Cited by 18 · see citing works
Effects of MPTP and vitamin E treatments on immune function in mice
Chi, D. S., Gong, L., Daigneault, E. A., & Kostrzewa, R. M. (1992) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(92)90070-2 · Cited by 18 · see citing works
Self-citationMicronutrients and Risk of Parkinson’s Disease
Sherzai, A. Z., Tagliati, M., Park, K., Pezeshkian, S., & Sherzai, D. (2016) · Gerontology and Geriatric Medicine · doi:10.1177/2333721416644286 · Cited by 15 · see citing works
Banerjee, P., Saha, I., Sarkar, D., & Maiti, A. K. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00501-x · Cited by 13 · see citing works
“However, controversial results in connection to systemic administration and prior treatment before MPTP administration failed to attenuate dopamine depletion (Martinovits et al. 1986; Gong et al. 1991; Offen et al. 1996); even the absence of protective action with stoppage of antioxidant administration was observed in…”
ResultIm, J. H., Yeo, I. J., Jeon, S. H., Lee, D. H., Ham, H. J., Yun, J., Han, S., & Hong, J. T. (2020) · doi:10.21203/rs.3.rs-19130/v1 · Cited by 5 · see citing works
Beyond 100 years of vitamin E and related molecules – Milestones and open challenges
Maria, W.-W., Jeffrey, A., Azzi, A., Bartolini, D., Birringer, M., Werner, B., Börmel, L., Consuelo, B., Cook‐Mills, J. M., Eggersdorfer, M. L., et al. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101477 · Cited by 2 · see citing works
Götz, M. E., Künig, G., Riederer, P. F., & Youdim, M. B. H. (1996) · Elsevier eBooks · doi:10.1016/b978-044482529-2/50039-1 · Cited by 1 · see citing works
de Sousa, D. Z., Pacheco, A. C. L., Cerqueira, G. S., Ferreira, P. M. P., Peron, A. P., & Calou, I. B. F. (2014) · Boletim Informativo Geum
Liu, Y., & Yan, Y. (2022) · Journal of Innovations in Medical Research · doi:10.56397/jimr/2022.10.02
- Authors
- Gong, L., Daigneault, E. A., Acuff, R. V., & Kostrzewa, R. M.
- Affiliations
- East Tennessee State University (US)
- Venue
- NeuroReport
- Published
- 1991-09
- Volume
- 2
- Issue
- 9
- Pages
- 544
- ISSN
- 0959-4965 (ISSN-L)
- OpenAlex
- W2021068090
- Cited by
- 28
- References
- 0
- Citations by year
- 2026: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 1 · 2016: 2 · 2015: 1 · 2014: 2
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroreport (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons - East Tennessee State University (East Tennessee State University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Biochemistry › Antioxidant Activity and Oxidative Stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- vitamin E, MPTP-induced neurotoxicity, MPTP, striatal dopamine depletion, neuroprotection, Parkinson's disease model, dietary supplementation
- MeSH terms
- Animals, Corpus Striatum, Dopamine, Male, Mice, Inbred C57BL, Parkinson Disease, Secondary, Vitamin E, MPTP Poisoning, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
